Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
30-day study of oral rivaroxaban in young children with venous thrombosis
2014-000566-22Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in Phlebothrombosis and venous thromboembolism (VTE), sponsored by Bayer. Primary endpoint: Composite of major and clinically relevant non-major bleeding. Started May 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Phlebothrombosisvenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2014-000566-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000566-22.